There are already several JAK inhibitors on the market – including Pfizer's own Xeljanz (abrocitinib) – while the TYK2 category is being led by Bristol-Myers Squibb's deucravacitinib ...
In the last few months, Pfizer has won approvals in the EU and US for JAK inhibitor Cibinqo (abrocitinib) as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief ...
Indias GDP made a significant leap achieving a remarkable growth rate of 8.4% in the third quarter of the FY 2024. This exceeded all expectations, as market analysts had predicted slower growth ...